Literature DB >> 25327401

The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis.

Kristin M Khalaf1, Karin S Coyne2, Denise R Globe3, Daniel C Malone4, Edward P Armstrong4, Vaishali Patel1, Jack Burks5.   

Abstract

AIMS: Lower urinary tract symptoms are commonly experienced among patients with multiple sclerosis (MS), however, their impact on health-related quality of life (HRQOL) has not been well characterized. Herein the incremental impact of lower urinary tract symptoms on HRQOL among patients with MS has been evaluated.
METHODS: A cross-sectional online survey was administered to US residents with a self-reported MS diagnosis. Data pertaining to demographics, disease history, urinary symptoms, and HRQOL, including the Short Form 36, version 2 (SF-36v2), were collected. Patients were stratified into four urinary symptom groups: no/minimal urinary symptoms, urinary urgency (UU), urinary urgency incontinence (UUI), and other lower urinary tract symptoms. Multiple linear regression models evaluated the impact of these symptoms.
RESULTS: Out of the 1,052 respondents, mean age was 47.8 ± 10.6 years; mean time since MS diagnosis was 8.5 ± 7.8 years. UUI and UU subgroups showed the greatest adjusted HRQOL decrement compared with the no/minimal urinary symptoms group, scoring 2.8 (SE ± 0.7, UUI) and 3.5 (SE ± 0.8, UU) points lower on SF-36v2 Physical Component Summary, respectively, and 3.7 (SE ± 1.0, UUI) and 5.0 (SE ± 1.2, UU) points lower on SF-36v2 Mental Component Summary (P < 0.001 for all), respectively.
CONCLUSIONS: Both UU and UUI symptoms contribute to a decrement in HRQOL among patients with MS. The Authors. Neurourology and Urodynamics published by Wiley Periodicals, Inc.

Entities:  

Keywords:  epidemiology; outcome assessment; quality of life

Mesh:

Year:  2014        PMID: 25327401     DOI: 10.1002/nau.22670

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  13 in total

Review 1.  Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.

Authors:  Aaron Kaviani; Rose Khavari
Journal:  Urol Clin North Am       Date:  2017-08       Impact factor: 2.241

Review 2.  Invasive Therapies in Multiple Sclerosis.

Authors:  Cihat Uzunköprü
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

3.  Functional Magnetic Resonance Imaging with Concurrent Urodynamic Testing Identifies Brain Structures Involved in Micturition Cycle in Patients with Multiple Sclerosis.

Authors:  Rose Khavari; Christof Karmonik; Michael Shy; Sophie Fletcher; Timothy Boone
Journal:  J Urol       Date:  2016-09-21       Impact factor: 7.450

4.  Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.

Authors:  Rose Khavari; Saba N Elias; Rashmi Pande; Katherine M Wu; Timothy B Boone; Christof Karmonik
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

Review 5.  Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

Authors:  Peter Joseph Jongen
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

Review 6.  The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.

Authors:  Jure Tornic; Jalesh N Panicker
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-28       Impact factor: 5.081

7.  Quality of life among patients with multiple sclerosis and voiding dysfunction: a cross-sectional study.

Authors:  Fatemeh Nazari; Vahid Shaygannejad; Mehrdad Mohammadi Sichani; Marjan Mansourian; Valiollah Hajhashemi
Journal:  BMC Urol       Date:  2020-06-03       Impact factor: 2.264

8.  What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT.

Authors:  Rafiyah Khan; Alan Uren; Luke Canham; David Cottrell; Marcus J Drake; Nikki Cotterill
Journal:  Mult Scler Int       Date:  2018-10-18

9.  Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.

Authors:  Hawra B Al Dandan; Susan Coote; Doreen McClurg
Journal:  Int J MS Care       Date:  2020 Mar-Apr

10.  Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.

Authors:  Mark Tullman; Emmanuel Chartier-Kastler; Alfred Kohan; Veronique Keppenne; Benjamin M Brucker; Blair Egerdie; Meryl Mandle; Jean Paul Nicandro; Brenda Jenkins; Pierre Denys
Journal:  Neurology       Date:  2018-07-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.